Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04419857
Other study ID # 2000028252
Secondary ID 2T35DK104689-06
Status Recruiting
Phase N/A
First received
Last updated
Start date December 4, 2020
Est. completion date May 2026

Study information

Verified date April 2023
Source Yale University
Contact Lisa Palmieri, BA
Phone 203-785-4651
Email lisa.palmieri@yale.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized clinical study in NAS infants managed via the Eat, Sleep, Console (ESC) approach comparing early weight loss on a standard-caloric density versus high-caloric density feeding regimen.


Description:

The aims of the study is to systematically evaluate the benefit of high-caloric diet regimens given to NAS infants in the first three weeks of life. Breastfeeding is the preferred feeding method for NAS infants as it has shown to reduce NAS severity and infant weight loss, though women who are not adherent to drug treatment programs or have the potential to use illicit drugs are not able to breastfeed due to the risks posed to the infant. Several studies have demonstrated the potential for caloric enhancement of formula and breast milk to support weight gain in NAS infants. Through a randomized control trial analyzing infant weight gain on standard-calorie vs. high-calorie diet regimens, we aim to quantify weight patterns in NAS infants and show that increasing caloric intake can improve weight gain.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date May 2026
Est. primary completion date May 2025
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Infant Inclusion Criteria: - Infants with NAS born to mothers age 18-45 with methadone exposure before or during pregnancy who do not intend to place their infants for adoption - Infants > 2200 g Infants at least 36 weeks gestational age - Delivered at: Yale New Haven Hospital - Mothers/infants able to return to outpatient pediatric provider for 2 month and 4 month weights visits Infant Exclusion Criteria: - Infants with major congenital malformations - Infants enrolled to NICU >24 hours for medical conditions other than NAS treatment before 3 days of life Mother's Inclusion criteria - - Pregnant women (age 18-45) who have started methadone treatment at obstetrics or other YNHH appointments - Confirm methadone treatment is received from a licensed treatment program - Confirm that mothers are planning to deliver their infant(s) at Yale New Haven Hospital - Confirm that mothers do not intend to place the infant(s) for adoption - Confirm mother's willingness to participate in the study (including attending the 2-month and 4-month follow up weigh-ins with pediatrician) - Consent forms will be signed and faxed to study staff

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
High-calorie formula
Infant randomly assigned to high-calorie formula for 14 days

Locations

Country Name City State
United States Yale New Haven Hospital New Haven Connecticut

Sponsors (2)

Lead Sponsor Collaborator
Yale University National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximal percent weight loss compared to birth weight this will be measured by twice daily weights while in the hospital and once daily weights at home for two weeks after birth compared with birth weight 2 weeks
Secondary Hours to weight nadir Measured by determining the hours of life that the maximal percent weight loss was obtained for each patient, assessed within the first two weeks after birth 2 weeks
Secondary Days to return to birthweight Measured by determining the days of life each patient regained birthweight, assessed within the first month after birth 1 month
Secondary Percent weight change per day Measured by comparing the weight from the weight obtained the day prior, assessed daily for the first two weeks after birth 2 weeks
Secondary Length of hospital stay Measured by comparing admission time to discharge time, assessed at hospital discharge up to 6.5 days
See also
  Status Clinical Trial Phase
Completed NCT01965704 - Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women Phase 2
Completed NCT03890562 - Assessing the Effects of Auricular Acupressure on Newborns With NAS N/A
Completed NCT01958476 - Improving Outcomes in Neonatal Abstinence Syndrome Phase 3
Active, not recruiting NCT01734551 - NAS Treatment - Opiate Versus Non-Opiate Phase 4
Completed NCT00496951 - Vagal Tone and Neonatal Abstinence Syndrome N/A
Completed NCT02851303 - Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome Phase 4
Recruiting NCT05226624 - The Alberta Neonatal Abstinence Syndrome Mother-Baby Care ImprovEmeNT Program N/A
Completed NCT03670160 - Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome Phase 2
Not yet recruiting NCT04611659 - Averting NAS Among Opioid-Using Young Women Receiving MAT Using Buprenorphine N/A
Completed NCT01452789 - Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome Phase 3
Completed NCT04588519 - tAN to Mitigate Withdrawal Behaviors in Neonates N/A
Completed NCT02797990 - Conflict Between Maternal Autonomy and Child Health in Substance-use N/A
Completed NCT02801331 - Efficacy and Outcomes of a Non-Pharmacological Intervention for Neonatal Abstinence Syndrome N/A
Terminated NCT03246243 - Quantitative Assessment of Sucking for Early Diagnosis of Brain Injury in Infants at High Risk
Completed NCT03567603 - Sound Processing Changes in Babies With Opioid Exposure
Recruiting NCT06303986 - Study to Collect Data for Neonatal Abstinence Syndrome (NAS) and Evaluate the Automated Data Collection Process
Active, not recruiting NCT03725332 - The PATH Home Trial: A Comparative Effectiveness Study of Peripartum Opioid Use Disorder in Rural Kentucky N/A
Recruiting NCT04983563 - Actigraphy and Neonatal Abstinence Syndrome of Hospitalized Newborn in Intensive Care Units N/A
Completed NCT04298853 - Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome Phase 4
Completed NCT02182973 - Donor Human Milk in Neonatal Abstinence Syndrome